OneSource Backs Canada's Second Generic Semaglutide Approval in Key Market
OneSource Specialty Pharma supports its partner Orbicular in securing Health Canada approval for generic semaglutide injection, establishing the second generic approval in Canada's strategically important semaglutide market. The company will provide commercial supply from its US FDA-approved Bengaluru facility, reinforcing its global CDMO capabilities in complex drug-device combinations.
*this image is generated using AI for illustrative purposes only.
OneSource Specialty Pharma announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in what is recognized as the world's second-largest semaglutide market.
Strategic Market Milestone
The latest regulatory approval represents a significant achievement for OneSource's expanding portfolio of complex pharmaceutical partnerships in one of the world's most important semaglutide markets. The milestone reflects a closely integrated development and manufacturing model where Orbicular led the product development and technical program for the complex peptide, while OneSource supported the program as the manufacturing partner.
| Parameter: | Details |
|---|---|
| Product: | Generic Ozempic® (semaglutide injection) |
| Partner: | Orbicular with Canadian front-end partner |
| Market Position: | Second generic approval in Canada |
| Market Significance: | World's second-largest semaglutide market |
| Regulatory Authority: | Health Canada |
| Manufacturing Partner: | OneSource Specialty Pharma |
Manufacturing and Supply Chain Excellence
OneSource provided end-to-end manufacturing capabilities for the Canadian filing, with commercial supply to be supported from the company's US FDA-approved flagship facility in Bengaluru. The approval follows a recent tentative approval in the United States supported by OneSource, further reinforcing the company's growing presence in complex peptide-based injectable programs across highly regulated markets.
| Manufacturing Details: | Information |
|---|---|
| Supply Facility: | US FDA-approved Bengaluru facility |
| Manufacturing Role: | End-to-end manufacturing capabilities |
| Program Type: | Complex drug-device-combination |
| Market Coverage: | Highly regulated global markets |
Global Market Expansion
The Canadian approval builds on momentum from India, where OneSource has been supplying multiple brands marketed by various partners following product launches in March. This strategic positioning establishes the company as a key player in the global semaglutide market across multiple jurisdictions, with particular strength in enabling first-to-market generic entries.
Mr. Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, commented: "We are pleased with these back-to-back approvals from two of our global customers in one of the most important semaglutide markets globally. This milestone reflects the strength of our CDMO platform, our compliance standards, technical expertise, and ability to scale complex drug-device-combination programs for highly regulated markets. Our partnership with Orbicular highlights our role in enabling global commercialization through strong, collaborative ecosystems."
CDMO Platform Capabilities
With a continued focus on complex drug-device combinations, biologics, and oral technology, OneSource is strengthening its position as a global CDMO partner. The company enables faster, reliable, and high-quality commercialization for partners worldwide through its comprehensive manufacturing and development capabilities across five state-of-the-art facilities.
| Company Highlights: | Details |
|---|---|
| Manufacturing Facilities: | Five state-of-the-art facilities |
| Regulatory Approvals: | Global regulatory authorities |
| Team Size: | Over 1,600 professionals |
| Specialization: | Complex pharmaceutical products |
| Focus Areas: | Biologics, drug-device combinations, sterile injectables |
Historical Stock Returns for Onesource Specialty Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.07% | -0.31% | -1.03% | +12.19% | +2.33% | +5.59% |
How will the entry of generic semaglutide competitors impact Novo Nordisk's Ozempic pricing strategy and market share in Canada?
What regulatory hurdles might OneSource face when seeking approvals for generic semaglutide in other major markets like Europe and Japan?
Could OneSource's success with complex peptide manufacturing attract partnerships with other major pharmaceutical companies developing GLP-1 receptor agonists?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
